<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856570</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-040</org_study_id>
    <secondary_id>EudraCT 2008-000211-15</secondary_id>
    <nct_id>NCT00856570</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects</brief_title>
  <official_title>An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether YM178 has an effect on the pharmacokinetics of warfarin, to
      exclude any drug-drug interaction between YM178 and warfarin, and evaluates the safety and
      tolerability of warfarin alone and combined with YM178.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R- and S-warfarin in plasma: AUCinf, AUClast, Cmax, tmax, t1/2, CL/F</measure>
    <time_frame>Day 1-9 and 15-31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUCinf of both enantiomers will be used to assess the potential drug-drug interaction.</measure>
    <time_frame>Day 1/2 and 15/16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events, clinical laboratory tests (hematology, biochemistry, urinalysis), vital signs, 12-lead ECG, physical examination</measure>
    <time_frame>Day -1 - 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>YM178 in plasma: Ctrough, AUCtau, Cmax, tmax, CL/F</measure>
    <time_frame>Day 20-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of anticoagulation: AUCPT;0-168h (area under the prothrombin time versus time curve from 0 to 168 h after dosing with warfarin), AUCINR;0-168h, maximum PT (PTmax), time to reach PTmax (tPT; max), INRmax, tINR;max</measure>
    <time_frame>Day 1-9 and 23-31</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Pharmacokinetics</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>Oral</description>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM178</intervention_name>
    <description>Oral</description>
    <other_name>mirabegron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subject must be of non-child bearing potential, i.e. postmenopausal, surgically
             sterilized (e.g. tubal ligation), hysterectomy in medical history, or must practice
             adequate (double barrier) non-hormonal contraceptive methods to prevent pregnancies.

          -  Body Mass Index (BMI) â‰¥ 18.5 and &lt; 30 kg/m2, inclusive

        Exclusion Criteria:

          -  Female who is pregnant

          -  Any of the liver function tests (i.e. alanine aminotransferase (ALT), aspartate
             aminotransferase (AST) and Alkaline Phosphatase (AP)) above the upper limit of normal
             (ULN)

          -  Any clinically significant history of disease or disorder - gastrointestinal,
             cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric
             or metabolic as judged by the medical investigator

          -  Abnormal pulse and/or blood pressure measurements and the pre-study as follows: Pulse
             &lt; 40 or &gt; 90 bpm; mean systolic blood pressure &gt; 140 mmHg; mean diastolic blood
             pressure &gt; 90 mmHg (blood measurements taken in triplicate after subject has been
             resting in supine position for 5 min; pulse will be measured automatically

          -  A marked baseline prolongation of QT/QTc interval after repeated measurements of &gt;450
             ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias
             or torsades de pointes, structural heart disease, or a family history of Long QT
             Syndrome (LQTS)

          -  Use of any prescribed or OTC (over-the counter) drugs (including vitamins, natural and
             herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the
             Clinical Unit, except for paracetamol (up to 3 g/day)

          -  Any use of drugs of abuse within 3 months prior to admission to the clinical unit

          -  History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day
             within 3 months prior to admission to the clinical unit

          -  History of drinking more than 21 units of alcohol per week (1 unit = 270 ml of beer or
             40 ml of spirits or 1 glass of wine) (&gt; 14 units of alcohol for female subjects)
             within 3 months prior to admission to the clinical unit

          -  Donation of blood or blood products within 3 months prior to admission to the clinical
             unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=669</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YM178</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>DDI</keyword>
  <keyword>Phase I</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

